The approach is covered by patent application No. 62/219020, filed on September 15, 2015, which was developed out of intellectual property purchased from OmniBiome Therapeutics Inc.

"The current patent filing is a continuation of the Company's focus on leveraging immunological processes to diagnose and intervene in niche areas of unmet medical needs," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

Mr. Dixon added, "Specific biological molecules termed cytokines that are involved in the immune system killing cancer also appear to be involved in stimulating preterm labor and in extreme cases pregnancy loss. In our previous patent filings we cover means of modulating these molecules, either to fight cancer, or to prevent pregnancy complications. In the current patent filing we utilize advanced techniques to detect modulations of these molecules in the body, so as to potentially interfere at an early stage and hopefully preserve a healthy pregnancy."

The Company currently is marketing ProJuvenol™, a pterostilbene based nutraceutical, which has been demonstrated by independent groups to modulate cytokines such as TNF-alpha1, and interleukin-12 which are involved in pregnancy complications3. Additionally, the Company reported data showing its probiotic mixture is effective at reducing pregnancy loss in a mouse model of immunologically mediated miscarriage4.

"We aim to create products that on the one hand assist the physician at identifying potential pregnancy problems early, when intervention conceptually is more effective, as well as products that may modulate the biological cascades which lead to pregnancy complications. Currently we are seeking clinical collaborators and partners to accelerate the development of our approaches" said Mr. Dixon.

These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.